SC18

SC18, Inc. is a biotechnology company that operates as a subsidiary of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech). The company focuses on the discovery and development of novel therapeutic agents, particularly antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology indications. SC18 serves as a key research and development arm for its parent company, leveraging a proprietary ADC platform to target high-unmet-need cancers such as triple-negative breast cancer and non-small cell lung cancer. Its pipeline includes several advanced candidates that have been the subject of major global licensing agreements with pharmaceutical leaders like Merck & Co. (MSD).